The Role of SPINK1 in ETS Rearrangement-Negative Prostate Cancers Review uri icon


MeSH Major

  • Biomarkers, Tumor
  • Carrier Proteins
  • Gene Expression Regulation, Neoplastic
  • Gene Rearrangement
  • Prostatic Neoplasms
  • Proto-Oncogene Proteins c-ets


  • ETS gene fusions have been characterized in a majority of prostate cancers; however, the key molecular alterations in ETS-negative cancers are unclear. Here we used an outlier meta-analysis (meta-COPA) to identify SPINK1 outlier expression exclusively in a subset of ETS rearrangement-negative cancers ( approximately 10% of total cases). We validated the mutual exclusivity of SPINK1 expression and ETS fusion status, demonstrated that SPINK1 outlier expression can be detected noninvasively in urine, and observed that SPINK1 outlier expression is an independent predictor of biochemical recurrence after resection. We identified the aggressive 22RV1 cell line as a SPINK1 outlier expression model and demonstrate that SPINK1 knockdown in 22RV1 attenuates invasion, suggesting a functional role in ETS rearrangement-negative prostate cancers.


publication date

  • June 10, 2008



  • Review



  • eng

PubMed Central ID

  • PMC2732022

Digital Object Identifier (DOI)

  • 10.1016/j.ccr.2008.04.016

PubMed ID

  • 18538735

Additional Document Info

start page

  • 519

end page

  • 28


  • 13


  • 6